Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + corticosteroid
- Development stage
- Preclinical
- Lead developer
- Lupvindol
- Modality
- Small Molecules
01
Overview
Lupvindol Biosciences is developing a fixed-dose combination (FDC) therapy that combines cannabidiol (CBD) with a low-dose corticosteroid for the treatment of autoimmune and inflammatory conditions. This small molecule combination leverages CBD's activity on cannabinoid receptors (CB1 and CB2) alongside the corticosteroid's action on the glucocorticoid receptor to produce super-additive anti-inflammatory and immunomodulatory effects. The primary goal of this approach is to serve as a steroid-sparing agent, allowing for reduced corticosteroid dosages and thereby minimizing the adverse effects associated with long-term or high-dose steroid use. While the company is pursuing a veterinary-first strategy (e.g., for canine inflammatory bowel disease), it is also advancing the program toward human Phase III clinical development for various inflammatory disorders.
- Other names
- CBD + Corticosteroid FDCfixed-dose combination of CBD and corticosteroids
02
Targets
CNR1 (Cannabinoid receptor 1)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on cannabidiol + corticosteroid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + corticosteroid.